News
Cancer treatment is first to
directly target tumor blood vessels in patients
By Krishna Ramanujan Original Source:
Cornell Chronicle
March 2007
A clinical trial has for the first time proven that an antibody called J591 specifically targets an antigen found in high amounts on both prostate tumors and on blood vessels of all solid tumors, according to a study by medical researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center in New York City. keep reading
Cancer Treatment Is First to Directly Target Tumor Blood Supply in Patients
Phase I Trial Confirms Targeting Ability of PSMA Antibody Treatment, a Potentially Major Advance in Cancer Care
New York (Feb 12, 2007)
For the first time, physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center in New York City have demonstrated in patients the ability of an antibody to directly target the blood supply of a wide variety of tumors, leaving healthy tissues unharmed. keep reading
Radioimmunotherapy of Prostate
Cancer Using 90Y- and 177Lu-LabeledJ591Monoclonal Antibodies: Effect of Multiple
Treatments on Myelotoxicity
Shankar Vallabhajosula,1Stanley J. Goldsmith,1Lale Kostakoglu,1 Mathew I.
Milowsky, 2, 3 David M. Nanus, 2, 3 and Neil H.Bander3
October 1, 2005
Purpose: Bone marrow is the dose-limiting organ in radioimmunotherapy. Fractionated dose regimens may decrease myelotoxicity and increase greater total administered dose. We have studied the effect of two or three treatments of 177Lu-J591and 90Y-J591monoclonal antibodies (mAb) on myelotoxicity. keep reading
Phase I Trial of Yttrium-90—Labeled
Anti—Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for
Androgen-Independent Prostate Cancer
Matthew I. Milowsky, David M. Nanus, Lale Kostakoglu, Shankar Vallabhajosula,
Stanley J. Goldsmith, Neil H. Bander
From the Division of Hematology and Medical Oncology, Department of Medicine,
Division of Nuclear Medicine, Department of Radiology, and Department of
Urology, Weill Medical College of Cornell University, New York, NY
May 31, 2003
Purpose: To determine the maximum-tolerated dose (MTD), toxicity, human antihuman antibody (HAHA) response, pharmacokinetics, organ dosimetry, targeting, and preliminary efficacy of yttrium-90–labeled anti–prostate-specific membrane antigen monoclonal antibody J591 (90Y-J591) in patients with androgen-independent prostate cancer (PC). keep reading
Vascular Targeted Therapy With Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Advanced Solid Tumors -- Milowsky et al. 25 (5): 540 -- Journal of Clinical Oncology
Matthew I. Milowsky, David M. Nanus, Lale Kostakoglu, Christine E. Sheehan, Shankar Vallabhajosula, Stanley J. Goldsmith, Jeffrey S. Ross, Neil H. Bander
From the Division of Hematology and Medical Oncology, Department of Medicine, Division of Nuclear Medicine, Department of Radiology, Department of Urology, Weill Medical College of Cornell University, New York; and Department of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY
May 18, 2002
Purpose: Based on prostate-specific membrane antigen (PSMA) expression on the vasculature of solid tumors, we performed a phase I trial of antibody J591, targeting the extracellular domain of PSMA, in patients with advanced solid tumor malignancies. This was a proof-of-principle evaluation of PSMA as a potential neovascular target. The primary end points were targeting,toxicity, maximum-tolerated dose, pharmacokinetics (PK), and human antihuman antibody (HAHA) response. keep reading
Prognostic Value of [18F]Fluorodeoxyglucose Positron Emission Tomographic Scanning in Patients with Thyroid Cancer
1 Weiping Wang, Steven M. Larson, Melissa Fazzari,
Satish K. Tickoo, Katherine Kolbert, George Sgouros, Henry Yeung, Homer
Macapinlac, Juan Rosai and Richard J. Robbins
Nuclear Medicine and Endocrinology Services, Departments of Radiology (W.W.,
S.M.L., H.Y., H.M.), Medicine (R.R.), Medical Physics (K.K., G.S.), Epidemiology
and Biostatistics (M.F.), and Pathology (S.T., J.R.), The Laurent and Alberta
Gerschel PET Center, Memorial Sloan Kettering Cancer Center, New York, New York
10021
November 30, 1999
Abstract
Poorly differentiated thyroid cancer lesions often lose the ability to concentrate radioactive [131I]iodine (RAI) and exhibit increased metabolic activity, as evidenced by enhanced glucose uptake. We incorporated [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) scanning into the routine follow-up of a cohort of thyroid cancer patients undergoing annual evaluations. One hundred and twenty-five patients who had previous thyroidectomies were included. They had diagnostic RAI whole body scans, serum thyroglobulin measurements, and additional imaging studies as clinically indicated. During 41 months of follow-up, 14 patients died. Univariate analysis demonstrated that survival was reduced in those with age over 45 yr, distant metastases, PET positivity, high rates of FDG uptake, and high volume of the FDG-avid disease (>125 mL). Survival did not correlate with gender, RAI uptake, initial histology, or grade. Multivariate analysis demonstrated that the single strongest predictor of survival was the volume of FDG-avid disease. The 3-yr survival probability of patients with FDG volumes of 125 mL or less was 0.96 (95% confidence interval, 0.91, 1.0) compared with 0.18 (95% confidence interval, 0.04, 0.85) in patients with FDG volume greater than 125 mL. Only 1 death (of leukemia) occurred in the PET-negative group (n = 66). Of the 10 patients with distant metastases and negative PET scans, all were alive and well. Patients over 45 yr with distant metastases that concentrate FDG are at the highest risk. Once distant metastases are discovered in patients with differentiated thyroid carcinoma, FDG-PET can identify high and low risk subsets. Subjects with a FDG volume greater than 125 mL have significantly reduced short term survival. keep reading